{"id":"anti-pandemic-h1n1-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain, redness, or swelling"},{"rate":"1-5","effect":"Fever"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This inactivated influenza vaccine contains viral antigens (typically hemagglutinin and neuraminidase from H1N1 strain) that trigger both humoral and cell-mediated immune responses. Upon vaccination, B cells produce neutralizing antibodies against the virus, while T cells develop memory to recognize and eliminate infected cells, providing protection against H1N1 infection.","oneSentence":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against H1N1 influenza virus antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:03.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of H1N1 influenza infection during pandemic periods"}]},"trialDetails":[{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626},{"nctId":"NCT01151644","phase":"PHASE4","title":"Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2010-04","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE)","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anti-pandemic H1N1 influenza vaccine","genericName":"Anti-pandemic H1N1 influenza vaccine","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Biologic","firstApprovalDate":"","aiSummary":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against H1N1 influenza virus antigens. Used for Prevention of H1N1 influenza infection during pandemic periods.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}